Pro Bono Bio Lands $600M to Back its Nanotech Platform
By Nuala Moran
Tuesday, September 13, 2011
LONDON A new Anglo-Russian biopharmaceutical company has been formed with $300 million from the Russian government, matched by a further $300 million from investors in the London-based private equity firm Celtic Pharma Holdings.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.